The D2 antagonism is associated with its efficacy in the treatment of schizophrenia, while the potent 5-HT2A antagonism improves the negative symptoms of schizophrenia and reduces extrapyramidal side effects and prolactin levels. Here, PRL is linked to schizophrenia.